What are the grades of cytokine release syndrome (CRS) and how are they managed?

Cytokine Release Syndrome (CRS) Grading and Management

CRS is graded into 4 distinct categories based on fever, hypotension, and hypoxia, with management escalating from supportive care alone in Grade 1 to intensive ICU-level interventions with multiple immunosuppressive agents in Grade 4. 1

CRS Grade Definitions

Grade 1: Fever Only

• Clinical presentation: Temperature ≥38°C with no hypotension and no hypoxia 1, 2
• Key feature: Isolated fever without end-organ dysfunction
• Important caveat: After antipyretics or anti-IL-6 therapy are given, fever is NOT required to grade subsequent CRS severity—grading then depends solely on hypotension or hypoxia 1

Management:

• Supportive care with antipyretics, IV hydration, and symptomatic management 2
• Sepsis screen and empiric broad-spectrum antibiotics if neutropenic 1
• Consider G-CSF if neutropenic 1
• For prolonged CRS (>3 days) or in elderly/comorbid patients: Consider tocilizumab 8 mg/kg IV over 1 hour (max 800 mg) 1
• For specific CAR-T products (axicabtagene/brexucabtagene): Consider tocilizumab if symptoms persist >24 hours 1

Grade 2: Hypotension or Hypoxia (Mild)

• Clinical presentation: Temperature ≥38°C PLUS:
  • Hypotension NOT requiring vasopressors, OR
  • Hypoxia requiring low-flow nasal cannula (≤6 L/min) or blow-by 1, 2, 3
• Key feature: Hemodynamic or respiratory compromise manageable with basic interventions

Management:

• Tocilizumab 8 mg/kg IV over 1 hour (max 800 mg/dose) 1, 2
  • Repeat every 8 hours if no improvement
  • Maximum 3 doses in 24 hours, with 4 doses total 1
• Dexamethasone 10 mg IV every 12-24 hours for persistent refractory hypotension after 1-2 doses of tocilizumab 1
• IV fluid boluses as needed 2
• Cardiac monitoring until resolution to grade 1 or less 1
• Escalate to Grade 3 management if no improvement within 24 hours of starting tocilizumab 1

Grade 3: Hypotension or Hypoxia (Severe)

• Clinical presentation: Temperature ≥38°C PLUS:
  • Hypotension requiring a vasopressor (with or without vasopressin), OR
  • Hypoxia requiring high-flow nasal cannula, face mask, nonrebreather mask, or Venturi mask 1, 2, 3
• Key feature: Requires vasopressor support or high-flow oxygen

Management:

• Tocilizumab as per Grade 2 (if maximum dose not reached) 1
• Dexamethasone 10 mg IV every 6 hours 1
• Transfer to ICU 1, 3
• Obtain echocardiogram and perform hemodynamic monitoring 1
• Supplemental oxygen as needed 1
• If refractory, escalate to Grade 4 management 1

Grade 4: Life-Threatening Organ Dysfunction

• Clinical presentation: Temperature ≥38°C PLUS:
  • Hypotension requiring multiple vasopressors (excluding vasopressin), OR
  • Hypoxia requiring positive pressure ventilation (CPAP, BiPAP, intubation, mechanical ventilation) 1, 2, 3
• Key feature: Multi-organ failure requiring maximal life support

Management:

• Tocilizumab as per Grade 2 1
• Dexamethasone 10 mg IV every 6 hours 1
• If refractory: Methylprednisolone 1000 mg/day IV for 3 doses 1
  • If still refractory: Consider dosing every 12 hours 1
  • Alternative: Methylprednisolone 1000 mg/day × 3 days, then taper: 250 mg twice daily × 2 days, 125 mg twice daily × 2 days, 60 mg twice daily × 2 days 3
• ICU care with hemodynamic monitoring 1
• Mechanical ventilation as needed 1
• Symptomatic management of all organ toxicities 1

Critical Clinical Pearls

Timing and Recurrence

• Most CRS occurs during step-up dosing schedules with CAR-T or bispecific antibodies 1, 4, 5
• Approximately one-third of patients experience >1 CRS event 1, 4, 5
• Tocilizumab administration for first CRS event significantly reduces recurrence risk (20.0% vs 62.2% without tocilizumab) 4

Infection Considerations

• Always rule out infection before attributing fever to CRS 1
• Empiric broad-spectrum antibiotics are warranted in neutropenic patients 1
• Blood and urine cultures, chest radiograph if fever present 2

Antifungal Prophylaxis

• Strongly consider antifungal prophylaxis in patients receiving steroids for CRS treatment 1

Tocilizumab Conservation Strategies

Under conditions of limited tocilizumab availability 1:

• Limit tocilizumab to maximum 2 doses per CRS episode
• Use steroids more aggressively
• Consider siltuximab or anakinra as alternatives (very limited evidence)

Predictive Factors

• Longer time to fever onset, lower platelet count, and higher urea at presentation are associated with Grade 3-5 CRS 6
• Baseline tumor burden and cytokine levels do NOT reliably predict CRS incidence or severity 4, 5

Impact on Efficacy

• Tocilizumab and corticosteroid use for CRS management does NOT compromise response to immunotherapy 4, 5
• However, prolonged corticosteroid courses may be associated with shorter progression-free survival 3